Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20461995 | 0.80 | PIK3CD (0.53) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12573383 | 0.78 | PIK3CA (0.54) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL16660718 | 0.77 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29556703 | 0.77 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL116324 | 0.77 | PIK3CA (0.56) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL114826 | 0.77 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL25688980 | 0.76 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| Ammonia Solution, Strong SCHEMBL28553362 | 0.76 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17946250 | 0.75 | PIK3CD (0.50) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL15653035 | 0.75 | PIK3CD (0.50) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237073-A1 | Novel Polymorphs and Salts | GLAXO GROUP LTD (GB) | 2016-08-18 | — | — | US | disclosed |
| US-9353098-B2 | Polymorphs and salts | GLAXO GROUP LIMITED (GB) | 2016-05-31 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-20150299177-A1 | Novel Polymorphs and Salts | GLAXO GROUP LIMITED (GB) | 2015-10-22 | — | — | US | disclosed |
| US-9102668-B2 | Polymorphs and salts | GLAXO GROUP LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| EP-2614058-B1 | POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2015-07-08 | — | — | EP | disclosed |
| US-20140256721-A1 | Novel Polymorphs and Salts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-8735390-B2 | Polymorphs and salts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-05-27 | — | — | US | disclosed |
| EP-2614058-A1 | POLYMORPHS AND SALTS OF N- [5- [4- (5- { [(2R,6S) -2, 6 - DIMETHYL - 4 -MORPHOLINYL]METHYL} - 1, 3 - OXAZOL - 2 - YL) - 1H- INDA ZOL-6-YL]-2- (METHYLOXY) - 3 - PYRIDINYL]METHANESULFONAMIDE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| EP-2613781-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165441-A1 | Novel Polymorphs and Salts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032067-A1 | POLYMORPHS AND SALTS OF N- [5- [4- (5- { [(2R,6S) -2, 6 - DIMETHYL - 4 -MORPHOLINYL] METHYL} - 1, 3 - OXAZOL - 2 - YL) - 1H- INDA ZOL-6-YL] -2- (METHYLOXY) - 3 - PYRIDINYL] METHANESULFONAMIDE | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165441-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | PIK3CD 153/4885PIK3CA 133/4885PIK3CB 219/4885 |
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3CD 2938/4885PIK3CA 2691/4885PIK3CB 1706/4885 |
| US-20160237073-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | PIK3CD 153/4885PIK3CA 133/4885PIK3CB 219/4885 |
| US-20150299177-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | PIK3CD 153/4885PIK3CA 133/4885PIK3CB 219/4885 |
| US-20140256721-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | PIK3CD 153/4885PIK3CA 133/4885PIK3CB 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.